<DOC>
	<DOCNO>NCT01989221</DOCNO>
	<brief_summary>The aim study determine efficacy Sancuso® ( granisetron transdermal system ) 3.1 mg/24 hour improve symptom nausea vomit patient gastroparesis . This prospective open-label study use Sancuso® treat symptom nausea and/or vomiting patient diagnosed gastroparesis . Symptomatic patient diabetic idiopathic gastroparesis nausea and/or vomit enrol . The Gastroparesis Cardinal Symptom Index Daily Diary ( GCSI-DD ) use capture severity symptom , include nausea vomiting , baseline one week . Patients treat Sancuso® . Patients continue fill GCSI-DD daily basis undergo treatment Sancuso® two week . To determine Sancuso® treatment help improve symptom nausea vomit , symptom baseline compare symptom first week second week treatment . Thirty patient diagnose gastroparesis ( approximately 15 diabetic 15 idiopathic gastroparesis ) treat open label basis Sancuso® . The goal study demonstrate efficacy Sancuso® treat nausea and/or vomit gastroparesis patient . Safety information also collect regard adverse effect . If result encourage , expect base personal experience , large double blind study would appropriate .</brief_summary>
	<brief_title>Sancuso® Gastroparesis : An Open Label Study .</brief_title>
	<detailed_description>Objectives The aim study determine efficacy Sancuso® improving symptom nausea vomit patient gastroparesis . The specific objective study determine : 1 . Determine treatment response Sancuso® gastroparetic patient nausea and/or vomiting . 2 . Determine specific symptom gastroparesis improve - nausea , vomit , early satiety , abdominal distension , abdominal pain 3 . To determine symptomatic response diabetic idiopathic gastroparesis 4 . To determine time course symptom improvement ( Sancuso® symptoms gastroparesis ; The hypothesis test include : 1 . Sancuso® improve symptoms gastroparesis . 2 . Symptoms nausea vomit improve great degree abdominal pain . 3 . The beneficial response Sancuso® see diabetic idiopathic gastroparesis . 4 . The symptom reduction occur day 3 start treatment continue throughout treatment course .</detailed_description>
	<mesh_term>Gastroparesis</mesh_term>
	<mesh_term>Granisetron</mesh_term>
	<criteria>Age 18 65 year age Diagnosed gastroparesis patient symptoms gastroparesis least 3 month Symptoms nausea vomit least moderate severity use GCSI Prior history delay gastric emptying determine scintigraphy Gastroparesis either diabetic idiopathic etiology Symptoms nausea vomit respond adequately conventional antiemetic agent ( Compazine® , Tigan® ) Postsurgical gastroparesis Prolonged QTc EKG Prior intolerance 5HT3 antagonist ( ondansetron granisetron ) Known hypersensitivity granisetron component patch Current treatment ondansetron granisetron . Patients may stop medication one week enter study . Patients allow take ondansetron oral granisetron study . Use ketoconazole , medication know drugdrug interaction granisetron Women know pregnant , determined enrollment urine pregnancy test Women childbearing potential agree use medically approve form contraception Nursing mother</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>